Etosol Injection is a pharmaceutical formulation containing Etofylline (84.7 mg) and Theophylline (25.3 mg), designed for the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Etofylline, a xanthine derivative, acts as a bronchodilator by relaxing the smooth muscles of the airways, thereby improving airflow and alleviating bronchospasm. Theophylline, also a methylxanthine, complements this effect by inhibiting phosphodiesterase enzymes, leading to increased cyclic AMP levels and subsequent bronchodilation. Together, these active ingredients provide effective relief from symptoms like wheezing, shortness of breath, and chest tightness. Etosol Injection is typically administered intravenously or intramuscularly under medical supervision, ensuring rapid onset of action in acute exacerbations or when oral administration is not feasible. The combination therapy enhances respiratory function, reduces airway inflammation, and improves overall patient comfort. It is important to use Etosol Injection as prescribed, considering potential side effects such as nausea, headache, or palpitations. Caution is advised in patients with cardiovascular disorders, liver impairment, or hypersensitivity to xanthines. Regular monitoring of serum theophylline levels may be necessary to avoid toxicity. Etosol Injection offers a valuable therapeutic option for prompt and effective management of obstructive airway diseases.